Therapeutic challenges in hepatitis C-infected injection drug using patients

Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern. Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a complex treatment protocol that is often incompatible with the life styles of IDUs combine to acco...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Curtis L, Mills, Edward J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1664558/
https://www.ncbi.nlm.nih.gov/pubmed/17096852
http://dx.doi.org/10.1186/1477-7517-3-31
_version_ 1782131065167544320
author Cooper, Curtis L
Mills, Edward J
author_facet Cooper, Curtis L
Mills, Edward J
author_sort Cooper, Curtis L
collection PubMed
description Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern. Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a complex treatment protocol that is often incompatible with the life styles of IDUs combine to account for poor uptake and completion of HCV treatment. This article discusses HCV antiviral treatment issues relevant to IDUs chronically infected with this virus. The effect of non-injected substances of abuse on treatment outcome is considered. Priority issues requiring research are discussed.
format Text
id pubmed-1664558
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16645582006-11-30 Therapeutic challenges in hepatitis C-infected injection drug using patients Cooper, Curtis L Mills, Edward J Harm Reduct J Review Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern. Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a complex treatment protocol that is often incompatible with the life styles of IDUs combine to account for poor uptake and completion of HCV treatment. This article discusses HCV antiviral treatment issues relevant to IDUs chronically infected with this virus. The effect of non-injected substances of abuse on treatment outcome is considered. Priority issues requiring research are discussed. BioMed Central 2006-11-10 /pmc/articles/PMC1664558/ /pubmed/17096852 http://dx.doi.org/10.1186/1477-7517-3-31 Text en Copyright © 2006 Cooper and Mills; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Cooper, Curtis L
Mills, Edward J
Therapeutic challenges in hepatitis C-infected injection drug using patients
title Therapeutic challenges in hepatitis C-infected injection drug using patients
title_full Therapeutic challenges in hepatitis C-infected injection drug using patients
title_fullStr Therapeutic challenges in hepatitis C-infected injection drug using patients
title_full_unstemmed Therapeutic challenges in hepatitis C-infected injection drug using patients
title_short Therapeutic challenges in hepatitis C-infected injection drug using patients
title_sort therapeutic challenges in hepatitis c-infected injection drug using patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1664558/
https://www.ncbi.nlm.nih.gov/pubmed/17096852
http://dx.doi.org/10.1186/1477-7517-3-31
work_keys_str_mv AT coopercurtisl therapeuticchallengesinhepatitiscinfectedinjectiondrugusingpatients
AT millsedwardj therapeuticchallengesinhepatitiscinfectedinjectiondrugusingpatients

Ejemplares similares